Close

MIDAS

MIDAS

Online Portal for COVID-19 Modeling Research

Information and Resources for COVID-19 Modeling Research
Since late December 2019, a new Coronavirus infectious disease (COVID-19) has spread around the world. This global outbreak has been characterized as a pandemic by the World Health Organization. Researchers, students, and others in the Models of Infectious Disease Agent Study (MIDAS) create and use computational models to study transmission dynamics of a broad range of infectious diseases. Many MIDAS members are conducting research on COVID-19 and are contributing to an extraordinary international collection of data and information regarding the outbreak.
For general guidance and information about the global COVID-19 situation, follow information by the World Health Organization.
For guidance on the U.S. situation, see the U.S. CDC COVID-19 website.
For journalists and the general public, see the Software Catalog for a list of dashboards and visualizations to follow the COVID-19 pandemic.
For researchers and others interested in COVID-19 data and parameter estimates, see the Data and Information section.
For questions or ideas regarding COVID-19 modeling research, contact questions@midasnetwork.us.

COVID-19 General Announcements

MIDAS Webinar Series

Please see below for registration details for upcoming webinars. The webinars are open to the public and will be recorded, where possible.

  

    •  An expert judgment model to predict early stages of the COVID-19 outbreak in the United States 

Speaker: Dr. Thomas McAndrew, Postdoctoral Fellow of Biostatistics, University of Massachusetts at Amherst 

May 29, 12:00-1:00pm Eastern Time (US): Register now!

  

    • Confronting the Unknown: Immunopathology verses Protective Immunity in SARS-CoV-2 

Speaker: Dr. Micaela Martinez, Assistant Professor in Environmental Health Sciences, Columbia University 

June 26, 12:00-1:00pm Eastern Time (US): Register now!

 

    • Stochastic dynamical model of SARS-Cov-2 transmission in the US 

Speaker: Dr. John Drake, Distinguished Research Professor, Center for the Ecology of Infectious Diseases, University of Georgia 

July 31, 12:00-1:00pm Eastern Time (US): Register now!

 

    • Past events:

May 1st, 2020: A recording of the first MIDAS COVID-19 Webinar with Dr. Erin Mordecai is now available on the MIDAS Network YouTube channel and on the MIDAS website.

If you are interested in presenting your COVID-19 modeling research at a future MIDAS Webinar, please register here!

High Performance Computing Resources available for COVID-19 modeling research

The COVID-19 High Performance Computing (HPC) Consortium is providing free access to an unprecedented amount of HPC resources in support of COVID-19 research. The Consortium is a private-public effort bringing together partners from the federal government, industry, and academia. Interested researchers may submit proposals to the Consortium via an online portal, maintained by the Extreme Science and Engineering Discovery Environment (XSEDE). XSEDE is an NSF-funded virtual organization that integrates and coordinates the sharing of advanced digital services.  The Consortium steering group will  review proposals for matching with computing resources from one of the partner institutions. Infectious disease modelers working in collaboration with US CDC can also contact the Principal Investigator of XSEDE, John Towns at the University of Illinois directly (jtowns@ncsa.illinois.edu).

COVID-19 Funding Announcements

National Institutes of Health (NIH)

NIAID Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

On April 30, NIAID posted two new opportunities to provide an expedited funding mechanism for research on SARS-CoV-2 and COVID-19. PAR-20-177 uses the R21 mechanism, and PAR-20-178 uses the R01 grant mechanism.

Areas of high priority include:
  • Computational modeling studies to identify and evaluate interventions to protect at-risk populations and for making public health policy decisions for control and mitigation measures.
Applications will be accepted on a rolling basis, beginning on 4/30/2020.

NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. Applications for this initiative should be submitted through one of the funding opportunity announcements listed below, for deadlines starting April 5, 2020. Contact Dr. Erik Stemmy (erik.stemmy@nih.gov) or Wolfgang Leitner (wleitner@niaid.nih.gov) at NIAID for more information.

 

  • PA-19-052: NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
  • PA-19-053: NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
  • PA-18-591: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp - Clinical Trial Optional)
  • PA-19-056: NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
  • PA-19-272: PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
  • PA-19-270: PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)

NIAID Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

Researchers can request competitive revisions to existing NIAID grants, for COVID-19 research. NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. To apply, use PA-20-135; Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional). For more information, contact Dr. Diane Post (postd@niaid.nih.gov) or Wolfgang Leitner (wleitner@niaid.nih.gov) at NIAID.


NIGMS Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

Researchers can request competitive revisions to existing NIGMS grants, for COVID-19 research. NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest: (1) Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants); (2) Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only); (3) Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only). To apply, use PA-20-135; Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional). For more information, contact Dr. Diane Post (postd@niaid.nih.gov) or Wolfgang Leitner (wleitner@niaid.nih.gov) at NIAID.

National Science Foundation (NSF) RAPID Funding

NSF General COVID-19 RAPID Funding Announcement

In light of the emergence and spread of the coronavirus disease 2019 (COVID-19) in the United States and abroad, the National Science Foundation (NSF) is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.


NSF Office of Advanced Cyberinstrastucture participates in NSF RAPID funding for COVID-19 data and software infrastructure.

The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities. Such activities would be funded by the Computational and Data-Enabled Science and Engineering (CDS&E) program or the Cyberinfrastructure for Sustained Scientific Innovation (CSSI) program.


NSF Mathematical Biology in the Division of Mathematical Sciences also participates in NSF COVID-19 RAPID funding for mathematical modeling of COVID-19. Contact Zhilan Feng at the NSF Mathematical Biology Program (zfeng@nsf.gov).

NASA - COVID-19 Funding Opportunities

Principal investigators within NASA’s Earth Science Division (ESD) looking to reprioritize currently-funded efforts must reach out to their program manager(s) first to discuss this possibility. Up-front conversations ensure there is mutual understanding of potential impacts to current ESD-funded activities.
 
For new and/or additional support, see Program Element A.28 “Rapid Response and Novel Research in Earth Science” (RRNES) of Research Opportunities in Space and Earth Sciences (ROSES) 2020 as an opportunity to propose investigations making innovative use of NASA satellite data to address regional-to-global environmental, economic, and/or societal impacts of the COVID-19 pandemic. Potential proposals may address R&A-related topics more fundamental in underlying physical and/or biological sciences (including possible connections to socioeconomic activities) and/or ASP-related topics characterizing impacts of decisions or efforts to inform decision makers on regional-to-global levels in their responses to mitigate the impacts of the disease. While proposed studies must use NASA satellite data and information products as a primary source of information and research tools, they may also utilize remote sensing data and products from government agencies, international, or commercial sources. Studies utilizing Artificial Intelligence (AI) techniques including Machine Learning (ML) and Deep Learning (DL) are encouraged. A one-time allocation of ~$2M is identified for this opportunity. Proposals will undergo an internal review process by ESD staff, consulting the peer review community as needed. Reviews will be on a rolling basis as proposals are received and until the available funding is exhausted. For information, contact Dr. Laura Lorenzoni of ESD (laura.lorenzoni@nasa.gov)

Data and Information for COVID-19 Modeling

Disclaimer: Information listed in this section has been extracted from reputable scientific sources by the MIDAS Coordination Center and community members. This information should not be considered as endorsed by the MIDAS Coordination Center or its funding agency, the U.S. National Institutes of Health. Users should decide on the validity of each dataset or parameter estimate as they would for any other source of information used for scientific research.

Dataset Catalog

Public-access data collections with documented metadata. (Click on a collection name to see the collection in GitHub.)
TypeSPATIAL COVERAGECollection NameCreator(s)
Case countsSouth KoreaPress releases about nCoVKorean Centers for Disease Control
Case countsUnites States of AmericaCoronavirus (Covid 19) Data in the United StatesThe New York Times
Case countsUnites States of AmericaThe COVID Tracking ProjectThe Atlantic
Case countsChinaDistribution of new coronavirus pneumoniaChina CDC
Case countsHubei Provincehubey early deaths 2020 07 02Dorigatti I, et al.
Case countsChinaDistribution of new coronavirus pneumoniaChina CDC
Case countsChinaNumber of cumulative cases by Chinese prefecture from DXY.cnDXY.cn
Case countsEuropeSituation update for the EU/EEA, the UK and SwitzerlandEuropean Centre for Disease Prevention and Control
Case countsSingapore, MalaysiaDatasets for COVID 19 in Singapore and Malaysiaalphamodel
Case countsGlobalNovel Coronavirus (2019 nCoV) situation reportsWorld Health Organization
Case countsOntarioThe 2019 Novel Coronavirus (2019 nCoV), Status of cases in OntarioOntario Ministry of Health
Cases line listHong KongLatest local situation of Severe Respiratory Disease associated with a Novel Infectious AgentHong Kong Center for Health Protection
Cases line listSouth KoreaCOVID 19 South KoreaSang Woo Park
Cases line listSouth KoreaConfirmed patient movement routeKorean Centers for Disease Control
Cases line listGlobalWHO Novel Coronavirus Disease Outbreak NewsWorld Health Organization
Cases line listThailandNovel Coronavirus 2019 Pneumonia SituationEmergency Operation Center, Department of Disease Control
Cases line listThailandSituation report for citizens and the mediaEmergency Operation Center, Department of Disease Control
Cases line listGlobalnCoV line listings from DXY.cn maintained by NIH FogartySun K
Cases line listGlobalinternational cases 2020 08 02Dorigatti I, et al.
Cases line listGlobalGithub repository with nCoV line listings from various sources and data processing codemaintained by Oxford and others Gutierrez B, et al.
Cases line listGlobalnCoV line listings from various sources maintained by Oxford and othersGutierrez B, et al.
Cases line listCambodiaMinistry of Health Announcement on New Case of Coronavirus in Preah Sihanouk Province (2019 nCoV)Cambodia Ministry of Health
Data from papersChinaThe role of absolute humidity on transmission rate of the COVID 19 outbreakLuo W, et al.
Genome dataGlobalGenomic epidemiology of novel coronavirus (nCoV)Nextstrain
Mobility dataChinaBaidu mobility data for January through March, 2020Network Systems Science and Advanced Computing (University of Virginia)
Mobility dataGlobalCOVID 19 Community Mobility ReportsGoogle LLC
SurveyNACOVID 19 Expert SurveysMcAndrew T, et al.

Parameter Estimates - Peer-reviewed

Published estimates of epidemiological characteristics that have been peer-reviewed, encoded by community members and approved by authors. For complete information on each estimate, view this file on GitHub.
namevaluecountrylower boundupper boundage rangestart dateend datepublication datesource
Basic reproduction number2.36United StatesUnspecifiedUnspecifiedUnspecified2020-03-022020-03-252020-05-18Turk PJ, et al.
Basic reproduction number1.79United StatesUnspecifiedUnspecifiedUnspecified2020-03-022020-03-252020-05-18Turk PJ, et al.
Basic reproduction number1.33United StatesUnspecifiedUnspecifiedUnspecified2020-03-262020-04-072020-05-18Turk PJ, et al.
Basic reproduction number1.34United StatesUnspecifiedUnspecifiedUnspecified2020-03-262020-04-072020-05-18Turk PJ, et al.
Doubling time2.56United States2.113.25Unspecified2020-03-022020-03-252020-05-18Turk PJ, et al.
Doubling time2.94United States2.334Unspecified2020-03-022020-03-252020-05-18Turk PJ, et al.
Doubling time4.7United States3.776.22Unspecified2020-03-022020-04-072020-05-18Turk PJ, et al.
Doubling time4.01United States3.434.83Unspecified2020-03-022020-04-072020-05-18Turk PJ, et al.
Effective reproduction number2.9Spain2.673.14Unspecified2020-02-262020-03-062020-04-30Caicedo-Ochoa Y, et al.
Effective reproduction number2.83Italy2.72.96Unspecified2020-02-222020-03-022020-04-30Caicedo-Ochoa Y, et al.
Effective reproduction number3.95Ecuador3.74.21Unspecified2020-03-142020-03-242020-04-30Caicedo-Ochoa Y, et al.
Effective reproduction number3.67Panama3.254.13Unspecified2020-03-132020-03-232020-04-30Caicedo-Ochoa Y, et al.
Effective reproduction number2.91Brazil2.63.23Unspecified2020-03-092020-03-192020-04-30Caicedo-Ochoa Y, et al.
Effective reproduction number2.67Chile2.452.89Unspecified2020-03-152020-03-252020-04-30Caicedo-Ochoa Y, et al.
Effective reproduction number2.67Colombia2.382.98Unspecified2020-03-152020-03-252020-04-30Caicedo-Ochoa Y, et al.
Effective reproduction number2.36Peru2.112.63Unspecified2020-03-132020-03-232020-04-30Caicedo-Ochoa Y, et al.
Effective reproduction number2.42Mexico2.142.72Unspecified2020-03-122020-03-222020-04-30Caicedo-Ochoa Y, et al.
Proportion of hospitalized cases on mechanical ventilation0.202380952ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-01-302020-04-10Xie , et al.
Proportion of hospitalized cases on extracorporeal membrane oxygenation (ecmo)0.011904762ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-01-302020-04-10Xie , et al.
Effective reproduction number3.28ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-122020-04-10Maier BF, et al.
Effective reproduction number1.93ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-122020-04-10Maier BF, et al.
Effective reproduction number3.02ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-122020-04-10Maier BF, et al.
Effective reproduction number2.41ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-122020-04-10Maier BF, et al.
Effective reproduction number3.1ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-122020-04-10Maier BF, et al.
Effective reproduction number3.28ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-122020-04-10Maier BF, et al.
Effective reproduction number1.7ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-122020-04-10Maier BF, et al.
Effective reproduction number3.46ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-122020-04-10Maier BF, et al.
Effective reproduction number1.75ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-122020-04-10Maier BF, et al.
Effective reproduction number1.36ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-122020-04-10Maier BF, et al.
Incubation period4.2China3.55.1Unspecified2020-01-152020-01-202020-04-08Sanche S, et al.
Basic reprodutive number5.7China3.88.9Unspecified2020-01-152020-01-202020-04-08Sanche S, et al.
Growth rate0.27China0.210.29Unspecified2020-01-152020-01-202020-04-08Sanche S, et al.
Doubling time2.7China2.33.3Unspecified2020-01-152020-01-202020-04-08Sanche S, et al.
Time from symptom onset to hospitalization5.5China4.66.6UnspecifiedUnspecified2020-01-182020-04-08Sanche S, et al.
Time from symptom onset to hospitalization1.5China1.21.9Unspecified2020-01-192020-01-302020-04-08Sanche S, et al.
Time from hospitalization to recovery11.5China917.3Unspecified2020-01-152020-01-202020-04-08Sanche S, et al.
Time from hospitalization to death11.2China8.714.9Unspecified2020-01-152020-01-202020-04-08Sanche S, et al.
Time from symptom onset to death16.1China13.120.2Unspecified2020-01-152020-01-202020-04-08Sanche S, et al.
Proportion of hospitalized cases admitted to icu0.062264ChinaUnspecifiedUnspecifiedUnspecified2019-11-212020-01-312020-04-08Liang W, et al.
Proportion of hospitalized cases on mechanical ventilation0.031447ChinaUnspecifiedUnspecifiedUnspecified2019-11-212020-01-312020-04-08Liang W, et al.
Proportion of hospitalized cases that die0.031447ChinaUnspecifiedUnspecifiedUnspecified2019-11-212020-01-312020-04-08Liang W, et al.
Time from symptom onset to hospitalization5.7ChinaUnspecifiedUnspecifiedUnspecified2019-11-212020-01-312020-04-08Liang W, et al.
Time from symptom onset to hospitalization4.5ChinaUnspecifiedUnspecifiedUnspecified2019-11-212020-01-312020-04-08Liang W, et al.
Proportion of icu patients that die0.26Italy0.230.28Unspecified2020-02-202020-03-182020-04-06Grasselli G, et al.
Proportion of icu cases on mechanical ventilation0.88Italy0.870.9Unspecified2020-02-202020-03-182020-04-06Grasselli G, et al.
Proportion of icu cases on extracorporeal membrane oxygenation (ecmo)0.01Italy0.0030.02Unspecified2020-02-202020-03-182020-04-06Grasselli G, et al.
Duration of icu stay9Italy613Unspecified2020-02-202020-03-182020-04-06Grasselli G, et al.
Time from symptom onset to hospitalization5China3120-182020-01-312020-02-162020-04-06Han Y, et al.
Proportion of hospitalized cases treated with antivirals0ChinaUnspecifiedUnspecified0-182020-01-312020-02-162020-04-06Han Y, et al.
Proportion of hospitalized cases that die0ChinaUnspecifiedUnspecified0-182020-01-312020-02-162020-04-06Han Y, et al.
Proportion of hospitalized cases admitted to icu0ChinaUnspecifiedUnspecified0-182020-01-312020-02-162020-04-06Han Y, et al.
Proportion of hospitalized cases on mechanical ventilation0ChinaUnspecifiedUnspecified0-182020-01-312020-02-162020-04-06Han Y, et al.
Proportion of hospitalized cases on extracorporeal membrane oxygenation (ecmo)0ChinaUnspecifiedUnspecified0-182020-01-312020-02-162020-04-06Han Y, et al.
Time from symptom onset to hospitalization3.8China012Unspecified2020-12-242020-02-172020-04-02Zhang J, et al.
Time from symptom onset to hospitalization4.4China014Unspecified2020-12-242020-01-272020-04-02Zhang J, et al.
Time from symptom onset to hospitalization2.6China09Unspecified2020-01-282020-02-172020-04-02Zhang J, et al.
Incubation period5.2China1.812.4Unspecified2020-12-242020-02-142020-04-02Zhang J, et al.
Time from symptom onset to reporting7.4China118Unspecified2020-12-242020-02-172020-04-02Zhang J, et al.
Time from symptom onset to reporting8.9China219.8Unspecified2020-12-242020-01-272020-04-02Zhang J, et al.
Time from symptom onset to reporting5.4China112Unspecified2020-01-282020-02-172020-04-02Zhang J, et al.
Serial interval5.1China1.311.6Unspecified2020-12-242020-02-172020-04-02Zhang J, et al.
Proportion of hospitalized cases treated with antivirals0.235294118SingaporeUnspecifiedUnspecifiedUnspecified2020-01-182020-02-102020-03-28Pung R, et al.
Proportion of hospitalized cases admitted to icu0.117647059SingaporeUnspecifiedUnspecifiedUnspecified2020-01-182020-02-102020-03-28Pung R, et al.
Proportion of hospitalized cases that die0SingaporeUnspecifiedUnspecifiedUnspecified2020-01-182020-02-102020-03-28Pung R, et al.
Time from symptom onset to hospitalization4Singapore39Unspecified2020-01-182020-02-102020-03-28Pung R, et al.
Proportion of hospitalized cases that die0ChinaUnspecifiedUnspecified16-1302020-02-072020-02-122020-03-27Wang , et al.
Time from symptom onset to hospitalization10China71416-1302020-02-072020-02-122020-03-27Wang , et al.
Proportion of hospitalized cases treated with antibiotics1ChinaUnspecifiedUnspecifiedUnspecified2020-01-072020-02-112020-03-24Chu , et al.
Proportion of hospitalized cases treated with antivirals0.574074ChinaUnspecifiedUnspecifiedUnspecified2020-01-072020-02-112020-03-24Chu , et al.
Proportion of hospitalized cases that die0.018519ChinaUnspecifiedUnspecifiedUnspecified2020-01-072020-02-112020-03-24Chu , et al.
Proportion of hospitalized cases on mechanical ventilation0.714285714United StatesUnspecifiedUnspecifiedUnspecified2020-02-202020-03-052020-03-19Arentz M, et al.
Proportion of hospitalized cases that die0.523809524United StatesUnspecifiedUnspecifiedUnspecified2020-02-202020-03-052020-03-19Arentz M, et al.
Time from symptom onset to hospitalization3.5United StatesUnspecifiedUnspecifiedUnspecified2020-02-202020-03-052020-03-19Arentz M, et al.
Time from hospitalization to mechanical ventilation1.5United States012Unspecified2020-02-202020-03-052020-03-19Arentz M, et al.
Proportion of hospitalized cases treated with antibiotics0.625ChinaUnspecifiedUnspecified0-182020-01-242020-02-242020-03-19Sun , et al.
Proportion of hospitalized cases treated with antivirals1ChinaUnspecifiedUnspecified0-182020-01-242020-02-242020-03-19Sun , et al.
Proportion of hospitalized cases on mechanical ventilation0.25ChinaUnspecifiedUnspecified0-182020-01-242020-02-242020-03-19Sun , et al.
Proportion of hospitalized cases that die0ChinaUnspecifiedUnspecified0-182020-01-242020-02-242020-03-19Sun , et al.
Effective reproduction number2.38China2.042.77Unspecified2020-01-102020-01-232020-03-16Li R, et al.
Latent period3.69China3.284.03Unspecified2020-01-102020-01-232020-03-16Li R, et al.
Transmission rate1.12China1.041.18Unspecified2020-01-102020-01-232020-03-16Li R, et al.
Cumulative case count13118China297423435Unspecified2020-01-102020-01-232020-03-16Li R, et al.
Cumulative case count16829China379730271Unspecified2020-01-102020-01-232020-03-16Li R, et al.
Effective reproduction number1.36China1.141.63Unspecified2020-01-242020-02-032020-03-16Li R, et al.
Latent period3.6China3.413.91Unspecified2020-01-242020-02-032020-03-16Li R, et al.
Reporting rate75.00%China60.00%69.00%Unspecified2020-01-242020-02-032020-03-16Li R, et al.
Transmission rate0.52China0.390.71Unspecified2020-01-242020-02-032020-03-16Li R, et al.
Effective reproduction number0.99China0.761.33Unspecified2020-01-242020-02-082020-03-16Li R, et al.
Latent period3.44China3.264.06Unspecified2020-01-242020-02-082020-03-16Li R, et al.
Transmission rate0.35China0.270.5Unspecified2020-01-242020-02-082020-03-16Li R, et al.
Proportion of infections acquired in hospital settings0.413043ChinaUnspecifiedUnspecified42-682020-01-012020-02-032020-02-07Wang D, et al.
Proportion of hospitalized cases treated with antibacterials1ChinaUnspecifiedUnspecified42-682020-01-012020-02-032020-02-07Wang D, et al.
Proportion of hospitalized cases treated with antivirals0.898551ChinaUnspecifiedUnspecified42-682020-01-012020-02-032020-02-07Wang D, et al.
Proportion of hospitalized cases admitted to icu0.26087ChinaUnspecifiedUnspecified42-682020-01-012020-02-032020-02-07Wang D, et al.
Proportion of icu patients that die0.166667ChinaUnspecifiedUnspecified42-682020-01-012020-02-032020-02-07Wang D, et al.
Proportion of hospitalized cases on mechanical ventilation0.123188ChinaUnspecifiedUnspecified42-682020-01-012020-02-032020-02-07Wang D, et al.
Proportion of hospitalized cases on extracorporeal membrane oxygenation (ecmo)0.028986ChinaUnspecifiedUnspecified42-682020-01-012020-02-032020-02-07Wang D, et al.
Proportion of hospitalized cases that die0.043478ChinaUnspecifiedUnspecified42-682020-01-012020-02-032020-02-07Wang D, et al.
Time from symptom onset to hospitalization7China4842-682020-01-012020-02-032020-02-07Wang D, et al.
Time from symptom onset to dyspena5China11042-682020-01-012020-02-032020-02-07Wang D, et al.
Time from symptom onset to ards8China61242-682020-01-012020-02-032020-02-07Wang D, et al.
Time from symptom onset to icu admission10China61242-682020-01-012020-02-032020-02-07Wang D, et al.
Duration of hospitalization10China71442-682020-01-012020-02-032020-02-07Wang D, et al.
Incubation period5.2China4.46Unspecified2019-12-012019-02-042020-02-04Lauer SA, et al.
Ascertainment rate0.092Japan0.050.2Unspecified2020-01-222020-01-292020-02-04Nishiura H, et al.
Cumulative case count75815China37304130330Unspecified2019-12-012020-01-252020-01-31Wu JT, et al.
Basic reproduction number2.24China1.962.55Unspecified2020-01-102020-01-242020-01-27Zhao S, et al.
Proportion of hospitalized cases that die0.14China0.0390.32UnspecifiedUnspecified2020-01-212020-01-21Wu P, et al.
Basic reproduction number0.3China0.170.44Unspecified2020-01-092020-01-112020-01-12Wu P, et al.

Parameter Estimates - Not peer-reviewed

Published estimates of epidemiological characteristics that have not been peer-reviewed, encoded by community members and approved by authors. For complete information on each estimate, view this file on GitHub.

namevaluecountrylower boundupper boundage rangestart dateend datepublication datesource
Incubation period6.4Vietnam4.898.5Unspecified2020-01-232020-04-132020-05-15Bui LV, et al.
Basic reproduction number3.56FranceUnspecifiedUnspecifiedUnspecified2020-02-152020-03-112020-05-01Unlu E, et al.
Effective reproduction number0.76FranceUnspecifiedUnspecifiedUnspecified2020-03-122020-05-012020-05-01Unlu E, et al.
Incubation period5.1FranceUnspecifiedUnspecifiedUnspecified2020-02-152020-05-012020-05-01Unlu E, et al.
Infection fatality ratio0.0083FranceUnspecifiedUnspecifiedUnspecified2020-02-152020-05-012020-05-01Unlu E, et al.
Proportion of infections symptomatic0.21FranceUnspecifiedUnspecifiedUnspecified2020-02-152020-05-012020-05-01Unlu E, et al.
Transmission rate0.34AlgeriaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01AlgeriaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.14AlgeriaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.09AlgeriaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.22ArgentinaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.05ArgentinaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.08ArgentinaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.04ArgentinaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.44AustraliaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01AustraliaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.18AustraliaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1AustraliaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.57AustriaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01AustriaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.23AustriaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1AustriaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.69BelgiumUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01BelgiumUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.28BelgiumUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.08BelgiumUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.7BrazilUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.03BrazilUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.28BrazilUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.06BrazilUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.68CanadaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.04CanadaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.27CanadaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.05CanadaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.49ChileUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.04ChileUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.2ChileUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.05ChileUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.26ColombiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01ColombiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.1ColombiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1ColombiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.45CzechiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01CzechiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.19CzechiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1CzechiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.22DenmarkUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.22DenmarkUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.08DenmarkUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.08DenmarkUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.26Dominican RepublicUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.1Dominican RepublicUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.1Dominican RepublicUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.01Dominican RepublicUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.32EcuadorUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01EcuadorUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.13EcuadorUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1EcuadorUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.22EgyptUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.14EgyptUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.08EgyptUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.03EgyptUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.18FinlandUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.18FinlandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.06FinlandUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.06FinlandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.64FranceUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01FranceUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.26FranceUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1FranceUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.73GermanyUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01GermanyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.29GermanyUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1GermanyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.18GreeceUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01GreeceUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.05GreeceUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.09GreeceUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.41IndiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.21IndiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.17IndiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.08IndiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.27IndonesiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.24IndonesiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.1IndonesiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.09IndonesiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.39IranUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01IranUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.16IranUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1IranUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.35IrelandUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.35IrelandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.14IrelandUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.14IrelandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.61IsraelUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.02IsraelUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.25IsraelUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.08IsraelUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.55ItalyUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01ItalyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.23ItalyUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1ItalyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.16JapanUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.32JapanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.04JapanUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.13JapanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.2LuxembourgUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01LuxembourgUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.07LuxembourgUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1LuxembourgUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.34MalaysiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.02MalaysiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.14MalaysiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.07MalaysiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.31MexicoUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.15MexicoUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.12MexicoUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.03MexicoUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.52NetherlandsUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01NetherlandsUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.21NetherlandsUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1NetherlandsUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.32NorwayUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.02NorwayUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.13NorwayUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.08NorwayUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.2PakistanUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.04PakistanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.07PakistanUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.05PakistanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.22PanamaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01PanamaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.08PanamaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1PanamaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.31PeruUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.31PeruUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.13PeruUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.13PeruUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.31PhilippinesUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.11PhilippinesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.12PhilippinesUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.01PhilippinesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.28PolandUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01PolandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.11PolandUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1PolandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.5PortugalUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01PortugalUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.21PortugalUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1PortugalUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.06QatarUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.38QatarUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate-0.03QatarUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.16QatarUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.59RomaniaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.03RomaniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.24RomaniaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.06RomaniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.47RussiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.32RussiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.2RussiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.13RussiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.24Saudi ArabiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.24Saudi ArabiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.09Saudi ArabiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.09Saudi ArabiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.29SerbiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.29SerbiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.12SerbiaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.12SerbiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.26SingaporeUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.24SingaporeUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.1SingaporeUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.09SingaporeUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.15South AfricaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.15South AfricaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.03South AfricaUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.03South AfricaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.6SpainUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01SpainUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.25SpainUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.08SpainUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.28SwedenUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01SwedenUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.11SwedenUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1SwedenUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.53SwitzerlandUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01SwitzerlandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.22SwitzerlandUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1SwitzerlandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.45ThailandUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.01ThailandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.19ThailandUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.1ThailandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.49TurkeyUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.12TurkeyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.2TurkeyUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.02TurkeyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.44United Arab EmiratesUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.19United Arab EmiratesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.18United Arab EmiratesUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate0.06United Arab EmiratesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.76United KingdomUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.05United KingdomUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.3United KingdomUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.04United KingdomUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Transmission rate0.72United StatesUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Transmission rate0.02United StatesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Growth rate0.29United StatesUnspecifiedUnspecifiedUnspecified2019-12-31Unspecified2020-04-26Romero-Severson E, et al.
Growth rate-0.07United StatesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-26Romero-Severson E, et al.
Basic reproduction number3.6Italy3.493.84Unspecified2020-02-222020-03-082020-04-23Gatto M, et al.
Growth rate0.2Belgium0.180.22Unspecified2020-03-062020-03-212020-04-15Ke R, et al.
Growth rate0.22France0.20.25Unspecified2020-02-292020-03-142020-04-15Ke R, et al.
Growth rate0.24Germany0.210.26Unspecified2020-03-012020-03-152020-04-15Ke R, et al.
Growth rate0.24Italy0.220.26Unspecified2020-02-232020-03-082020-04-15Ke R, et al.
Growth rate0.19Netherlands0.180.21Unspecified2020-03-062020-03-212020-04-15Ke R, et al.
Growth rate0.29Spain0.270.31Unspecified2020-03-022020-03-162020-04-15Ke R, et al.
Growth rate0.19Switzerland0.160.21Unspecified2020-03-052020-03-202020-04-15Ke R, et al.
Growth rate0.2United Kingdom0.180.22Unspecified2020-03-052020-03-202020-04-15Ke R, et al.
Growth rate0.28United States0.250.31Unspecified2020-03-032020-03-172020-04-15Ke R, et al.
Basic reproduction numberUnspecifiedglobal47.1Unspecified2020-01-202020-04-102020-04-15Ke R, et al.
Growth rate0.34United States0.310.37Unspecified2020-03-042020-03-312020-04-14Bliznashki S.
Growth rate0.23United States0.210.25Unspecified2020-03-042020-03-312020-04-14Bliznashki S.
Growth rate0.2United States0.180.23Unspecified2020-03-042020-03-312020-04-14Bliznashki S.
Secondary attack rate77.00%Canada63.00%83.00%5-14UnspecifiedUnspecified2020-04-09Tuite AR, et al.
Secondary attack rate63.00%Canada48.00%71.00%15-49UnspecifiedUnspecified2020-04-09Tuite AR, et al.
Secondary attack rate50.00%Canada37.00%58.00%0-5UnspecifiedUnspecified2020-04-09Tuite AR, et al.
Secondary attack rate47.00%Canada34.00%55.00%50-69UnspecifiedUnspecified2020-04-09Tuite AR, et al.
Secondary attack rate30.00%Canada21.00%36.00%70-130UnspecifiedUnspecified2020-04-09Tuite AR, et al.
Date of emergence2020-02-01United States2020-01-182020-02-09Unspecified2020-02-202020-03-152020-04-06Bedford T, et al.
Doubling time3.4United States2.45.1Unspecified2020-02-202020-03-152020-04-06Bedford T, et al.
Cumulative case count400United States801300Unspecified2020-01-152020-03-012020-04-06Bedford T, et al.
Cumulative case count9200000United States800000010100000Unspecified2020-03-15Unspecified2020-04-03Silverman JD, et al.
Doubling time2.52United States2.5192.521Unspecified2020-01-15Unspecified2020-04-03Silverman JD, et al.
Doubling time2.455United States2.4542.456Unspecified2020-01-15Unspecified2020-04-03Silverman JD, et al.
Case fatality ratio0.023ChinaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-02-112020-04-02Dudel C, et al.
Case fatality ratio0.04FranceUnspecifiedUnspecifiedUnspecifiedUnspecified2020-03-242020-04-02Dudel C, et al.
Case fatality ratio0.086SpainUnspecifiedUnspecifiedUnspecifiedUnspecified2020-03-162020-04-02Dudel C, et al.
Case fatality ratio0.016South KoreaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-03-302020-04-02Dudel C, et al.
Case fatality ratio0.106ItalyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-03-292020-04-02Dudel C, et al.
Case fatality ratio0.017United StatesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-03-162020-04-02Dudel C, et al.
Case fatality ratio0.012United StatesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-03-242020-04-02Dudel C, et al.
Case fatality ratio0.007GermanyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-03-292020-04-02Dudel C, et al.
Cumulative case count749911NA5615982814499UnspecifiedUnspecifiedUnspecified2020-04-01Liu Q, et al.
Cumulative case count184722NA178414206180UnspecifiedUnspecifiedUnspecified2020-04-01Liu Q, et al.
Cumulative case count420685NA2395465788917UnspecifiedUnspecifiedUnspecified2020-04-01Liu Q, et al.
Cumulative case count52686NA44867104299UnspecifiedUnspecifiedUnspecified2020-04-01Liu Q, et al.
Cumulative case count7247NA527317720UnspecifiedUnspecifiedUnspecified2020-04-01Liu Q, et al.
Cumulative case count27272NA2287949825UnspecifiedUnspecifiedUnspecified2020-04-01Liu Q, et al.
Basic reproduction number2.37AfghanistanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-152020-04-01Liu Q, et al.
Cumulative case count537AfghanistanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-152020-04-01Liu Q, et al.
Basic reproduction number2.51AlbaniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Cumulative case count400AlbaniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Basic reproduction number2.36AlgeriaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-042020-04-01Liu Q, et al.
Cumulative case count1389AlgeriaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-042020-04-01Liu Q, et al.
Basic reproduction number2.72AndorraUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-022020-04-01Liu Q, et al.
Cumulative case count690AndorraUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-022020-04-01Liu Q, et al.
Basic reproduction number2.42ArgentinaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-042020-04-01Liu Q, et al.
Cumulative case count2715ArgentinaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-042020-04-01Liu Q, et al.
Basic reproduction number2.6ArmeniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Cumulative case count599ArmeniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Basic reproduction number2.65AustraliaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Cumulative case count7247AustraliaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Basic reproduction number2.59AustriaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-07-252020-04-01Liu Q, et al.
Cumulative case count18671AustriaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-07-252020-04-01Liu Q, et al.
Basic reproduction number2.23AzerbaijanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-282020-04-01Liu Q, et al.
Cumulative case count428AzerbaijanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-282020-04-01Liu Q, et al.
Basic reproduction number2.01BahrainUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-092020-04-01Liu Q, et al.
Cumulative case count524BahrainUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-092020-04-01Liu Q, et al.
Basic reproduction number2.55BelgiumUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Cumulative case count15097BelgiumUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Basic reproduction number2.14Bosnia and HerzegovinaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-282020-04-01Liu Q, et al.
Cumulative case count678Bosnia and HerzegovinaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-282020-04-01Liu Q, et al.
Basic reproduction number2.7BrazilUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-082020-04-01Liu Q, et al.
Cumulative case count25424BrazilUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-082020-04-01Liu Q, et al.
Basic reproduction number2.48Brunei DarussalamUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-01Liu Q, et al.
Cumulative case count249Brunei DarussalamUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-01Liu Q, et al.
Basic reproduction number2.25BulgariaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-242020-04-01Liu Q, et al.
Cumulative case count1199BulgariaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-242020-04-01Liu Q, et al.
Basic reproduction number2.3Burkina FasoUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-062020-04-01Liu Q, et al.
Cumulative case count1218Burkina FasoUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-062020-04-01Liu Q, et al.
Basic reproduction number2.67CanadaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Cumulative case count13468CanadaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Basic reproduction number2.62ChileUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Cumulative case count5258ChileUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Basic reproduction number2.28ChinaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-032020-04-01Liu Q, et al.
Cumulative case count85166ChinaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-032020-04-01Liu Q, et al.
Basic reproduction number2.41ColombiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-212020-04-01Liu Q, et al.
Cumulative case count3744ColombiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-212020-04-01Liu Q, et al.
Basic reproduction number2.27Costa RicaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Cumulative case count821Costa RicaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Basic reproduction number2.55Côte d’IvoireUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-102020-04-01Liu Q, et al.
Cumulative case count1319Côte d’IvoireUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-102020-04-01Liu Q, et al.
Basic reproduction number2.67CroatiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-202020-04-01Liu Q, et al.
Cumulative case count1273CroatiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-202020-04-01Liu Q, et al.
Basic reproduction number2.29CyprusUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Cumulative case count438CyprusUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Basic reproduction number2.45Czech RepublicUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Cumulative case count5218Czech RepublicUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Basic reproduction number2.41DenmarkUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-152020-04-01Liu Q, et al.
Cumulative case count3555DenmarkUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-152020-04-01Liu Q, et al.
Basic reproduction number2.54Dominican RepublicUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-202020-04-01Liu Q, et al.
Cumulative case count2017Dominican RepublicUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-202020-04-01Liu Q, et al.
Basic reproduction number2.53EcuadorUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-262020-04-01Liu Q, et al.
Cumulative case count5191EcuadorUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-262020-04-01Liu Q, et al.
Basic reproduction number2.3EgyptUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-242020-04-01Liu Q, et al.
Cumulative case count844EgyptUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-242020-04-01Liu Q, et al.
Basic reproduction number2.68EstoniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-06-242020-04-01Liu Q, et al.
Cumulative case count838EstoniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-06-242020-04-01Liu Q, et al.
Basic reproduction number2.07Faroe IslandsUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-092020-04-01Liu Q, et al.
Cumulative case count226Faroe IslandsUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-092020-04-01Liu Q, et al.
Basic reproduction number2.2FinlandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-262020-04-01Liu Q, et al.
Cumulative case count1702FinlandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-262020-04-01Liu Q, et al.
Basic reproduction number3.61FranceUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-192020-04-01Liu Q, et al.
Cumulative case count63851FranceUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-192020-04-01Liu Q, et al.
Basic reproduction number2.72GermanyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-212020-04-01Liu Q, et al.
Cumulative case count105903GermanyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-212020-04-01Liu Q, et al.
Basic reproduction number2.53GhanaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-052020-04-01Liu Q, et al.
Cumulative case count4488GhanaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-052020-04-01Liu Q, et al.
Basic reproduction number2.27GreeceUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-192020-04-01Liu Q, et al.
Cumulative case count1496GreeceUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-192020-04-01Liu Q, et al.
Basic reproduction number2.27HungaryUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-272020-04-01Liu Q, et al.
Cumulative case count1084HungaryUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-272020-04-01Liu Q, et al.
Basic reproduction number2.15IcelandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-01Liu Q, et al.
Cumulative case count1524IcelandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-01Liu Q, et al.
Basic reproduction number2.41IndiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-092020-04-01Liu Q, et al.
Cumulative case count3326IndiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-092020-04-01Liu Q, et al.
Basic reproduction number2.43IndonesiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-132020-04-01Liu Q, et al.
Cumulative case count4638IndonesiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-132020-04-01Liu Q, et al.
Basic reproduction number3.55IranUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-112020-04-01Liu Q, et al.
Cumulative case count45932IranUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-112020-04-01Liu Q, et al.
Basic reproduction number2.86IraqUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-222020-04-01Liu Q, et al.
Cumulative case count668IraqUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-222020-04-01Liu Q, et al.
Basic reproduction number2.59IrelandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-292020-04-01Liu Q, et al.
Cumulative case count5707IrelandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-292020-04-01Liu Q, et al.
Basic reproduction number2.78IsraelUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-252020-04-01Liu Q, et al.
Cumulative case count10740IsraelUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-252020-04-01Liu Q, et al.
Basic reproduction number2.67ItalyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Cumulative case count127283ItalyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Basic reproduction number3.22JapanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-242020-04-01Liu Q, et al.
Cumulative case count1737JapanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-242020-04-01Liu Q, et al.
Basic reproduction number2.28JordanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-102020-04-01Liu Q, et al.
Cumulative case count949JordanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-102020-04-01Liu Q, et al.
Basic reproduction number2.33KazakhstanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-042020-04-01Liu Q, et al.
Cumulative case count2329KazakhstanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-042020-04-01Liu Q, et al.
Basic reproduction number2.31KoreaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-082020-04-01Liu Q, et al.
Cumulative case count10451KoreaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-082020-04-01Liu Q, et al.
Basic reproduction number1.68KuwaitUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-202020-04-01Liu Q, et al.
Cumulative case count295KuwaitUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-202020-04-01Liu Q, et al.
Basic reproduction number2.23LatviaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-282020-04-01Liu Q, et al.
Cumulative case count600LatviaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-282020-04-01Liu Q, et al.
Basic reproduction number2.2LebanonUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-252020-04-01Liu Q, et al.
Cumulative case count786LebanonUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-252020-04-01Liu Q, et al.
Basic reproduction number2.73LithuaniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-06-102020-04-01Liu Q, et al.
Cumulative case count1069LithuaniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-06-102020-04-01Liu Q, et al.
Basic reproduction number2.44LuxembourgUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-202020-04-01Liu Q, et al.
Cumulative case count4316LuxembourgUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-202020-04-01Liu Q, et al.
Basic reproduction number2.39MalaysiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Cumulative case count4296MalaysiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Basic reproduction number2.22MaltaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-262020-04-01Liu Q, et al.
Cumulative case count310MaltaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-262020-04-01Liu Q, et al.
Basic reproduction number2.36MexicoUnspecifiedUnspecifiedUnspecifiedUnspecified2020-06-172020-04-01Liu Q, et al.
Cumulative case count4308MexicoUnspecifiedUnspecifiedUnspecifiedUnspecified2020-06-172020-04-01Liu Q, et al.
Basic reproduction number2.28MoldovaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Cumulative case count775MoldovaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Basic reproduction number2.41MoroccoUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-152020-04-01Liu Q, et al.
Cumulative case count2397MoroccoUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-152020-04-01Liu Q, et al.
Basic reproduction number2.61NetherlandsUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-252020-04-01Liu Q, et al.
Cumulative case count20893NetherlandsUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-252020-04-01Liu Q, et al.
Basic reproduction number2.62New ZealandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-202020-04-01Liu Q, et al.
Cumulative case count2102New ZealandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-202020-04-01Liu Q, et al.
Basic reproduction number2.67North MacedoniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-172020-04-01Liu Q, et al.
Cumulative case count486North MacedoniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-172020-04-01Liu Q, et al.
Basic reproduction number2.34NorwayUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Cumulative case count7002NorwayUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Basic reproduction number2.21OmanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Cumulative case count230OmanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Basic reproduction number2.35PakistanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-132020-04-01Liu Q, et al.
Cumulative case count4939PakistanUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-132020-04-01Liu Q, et al.
Basic reproduction number2.64PanamaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-242020-04-01Liu Q, et al.
Cumulative case count2854PanamaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-242020-04-01Liu Q, et al.
Basic reproduction number2.29PeruUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-012020-04-01Liu Q, et al.
Cumulative case count3992PeruUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-012020-04-01Liu Q, et al.
Basic reproduction number2.35PhilippinesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-092020-04-01Liu Q, et al.
Cumulative case count2972PhilippinesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-092020-04-01Liu Q, et al.
Basic reproduction number2.51PolandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-242020-04-01Liu Q, et al.
Cumulative case count5586PolandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-242020-04-01Liu Q, et al.
Basic reproduction number2.66PortugalUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-052020-04-01Liu Q, et al.
Cumulative case count13108PortugalUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-052020-04-01Liu Q, et al.
Basic reproduction number2.46QatarUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Cumulative case count819QatarUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Basic reproduction number2.65RéunionUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-272020-04-01Liu Q, et al.
Cumulative case count429RéunionUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-272020-04-01Liu Q, et al.
Basic reproduction number2.52RomaniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Cumulative case count3413RomaniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-182020-04-01Liu Q, et al.
Basic reproduction number2.52RussiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-142020-04-01Liu Q, et al.
Cumulative case count6774RussiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-142020-04-01Liu Q, et al.
Basic reproduction number2.14San MarinoUnspecifiedUnspecifiedUnspecifiedUnspecified2020-06-042020-04-01Liu Q, et al.
Cumulative case count311San MarinoUnspecifiedUnspecifiedUnspecifiedUnspecified2020-06-042020-04-01Liu Q, et al.
Basic reproduction number2.47Saudi ArabiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-272020-04-01Liu Q, et al.
Cumulative case count4335Saudi ArabiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-272020-04-01Liu Q, et al.
Basic reproduction number2.34SenegalUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-292020-04-01Liu Q, et al.
Cumulative case count280SenegalUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-292020-04-01Liu Q, et al.
Basic reproduction number2.25SerbiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-212020-04-01Liu Q, et al.
Cumulative case count1481SerbiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-212020-04-01Liu Q, et al.
Basic reproduction number3.15SingaporeUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-01Liu Q, et al.
Cumulative case count847SingaporeUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-162020-04-01Liu Q, et al.
Basic reproduction number2.27SlovakiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-252020-04-01Liu Q, et al.
Cumulative case count879SlovakiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-252020-04-01Liu Q, et al.
Basic reproduction number2.76SloveniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-252020-04-01Liu Q, et al.
Cumulative case count1168SloveniaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-252020-04-01Liu Q, et al.
Basic reproduction number2.7South AfricaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-102020-04-01Liu Q, et al.
Cumulative case count13614South AfricaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-102020-04-01Liu Q, et al.
Basic reproduction number2.66SpainUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-222020-04-01Liu Q, et al.
Cumulative case count152539SpainUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-222020-04-01Liu Q, et al.
Basic reproduction number2.28Sri LankaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Cumulative case count200Sri LankaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Basic reproduction number2.21SwedenUnspecifiedUnspecifiedUnspecifiedUnspecified2020-07-232020-04-01Liu Q, et al.
Cumulative case count3974SwedenUnspecifiedUnspecifiedUnspecifiedUnspecified2020-07-232020-04-01Liu Q, et al.
Basic reproduction number2.64SwitzerlandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-242020-04-01Liu Q, et al.
Cumulative case count28290SwitzerlandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-242020-04-01Liu Q, et al.
Basic reproduction number2.32ThailandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-152020-04-01Liu Q, et al.
Cumulative case count5112ThailandUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-152020-04-01Liu Q, et al.
Basic reproduction number2.69The United KingdomUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-022020-04-01Liu Q, et al.
Cumulative case count41228The United KingdomUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-022020-04-01Liu Q, et al.
Basic reproduction number2.38TunisiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-282020-04-01Liu Q, et al.
Cumulative case count1723TunisiaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-282020-04-01Liu Q, et al.
Basic reproduction number3.11TurkeyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-062020-04-01Liu Q, et al.
Cumulative case count76824TurkeyUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-062020-04-01Liu Q, et al.
Basic reproduction number2.69UkraineUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-032020-04-01Liu Q, et al.
Cumulative case count10285UkraineUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-032020-04-01Liu Q, et al.
Basic reproduction number2.21United Arab EmiratesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Cumulative case count643United Arab EmiratesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-232020-04-01Liu Q, et al.
Basic reproduction number2.82United StatesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-072020-04-01Liu Q, et al.
Cumulative case count400892United StatesUnspecifiedUnspecifiedUnspecifiedUnspecified2020-05-072020-04-01Liu Q, et al.
Basic reproduction number2.64UruguayUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-262020-04-01Liu Q, et al.
Cumulative case count2030UruguayUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-262020-04-01Liu Q, et al.
Basic reproduction number2.42VenezuelaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-212020-04-01Liu Q, et al.
Cumulative case count657VenezuelaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-212020-04-01Liu Q, et al.
Basic reproduction number2.31Viet NamUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Cumulative case count211Viet NamUnspecifiedUnspecifiedUnspecifiedUnspecified2020-04-172020-04-01Liu Q, et al.
Transmission rate0.315BrazilUnspecifiedUnspecifiedUnspecified2020-02-262020-03-252020-03-30Crokidakis N.
Basic reproduction number5.25BrazilUnspecifiedUnspecifiedUnspecified2020-02-262020-03-252020-03-30Crokidakis N.
Doubling time2.72BrazilUnspecifiedUnspecifiedUnspecified2020-02-262020-03-252020-03-30Crokidakis N.
Serial interval4.95China-0.2910.19Unspecified2020-01-202020-02-192020-03-30Xu X, et al.
Serial interval5.19China-0.0910.47Unspecified2020-01-202020-02-192020-03-30Xu X, et al.
Case fatality ratio0.0048South KoreaUnspecifiedUnspecifiedUnspecified2020-01-232020-03-132020-03-29Lv B, et al.
Case fatality ratio0.017JapanUnspecifiedUnspecifiedUnspecified2020-01-232020-03-132020-03-29Lv B, et al.
Case fatality ratio0.043IranUnspecifiedUnspecifiedUnspecified2020-01-232020-03-132020-03-29Lv B, et al.
Case fatality ratio0.066ItalyUnspecifiedUnspecifiedUnspecified2020-01-232020-03-132020-03-29Lv B, et al.
Case fatality ratio0.029United StatesUnspecifiedUnspecifiedUnspecified2020-01-232020-03-132020-03-29Lv B, et al.
Case fatality ratio0.021FranceUnspecifiedUnspecifiedUnspecified2020-01-232020-03-132020-03-29Lv B, et al.
Case fatality ratio0.028SpainUnspecifiedUnspecifiedUnspecified2020-01-232020-03-132020-03-29Lv B, et al.
Basic reproduction number2.55Algeria2.152.93Unspecified2020-02-252020-03-222020-03-27Hamidouche M.
Basic reproduction number3.15China1.715.21Unspecified2020-01-23Unspecified2020-03-20Wangping J, et al.
Cumulative case count3988China7869065Unspecified2020-01-23Unspecified2020-03-20Wangping J, et al.
Basic reproduction number4.1Italy2.156.77Unspecified2020-03-09Unspecified2020-03-20Wangping J, et al.
Cumulative case count30086Italy792081869Unspecified2020-03-09Unspecified2020-03-20Wangping J, et al.
Basic reproduction number3.26Italy1.835.34Unspecified2020-03-05Unspecified2020-03-20Wangping J, et al.
Cumulative case count10636Italy235723326Unspecified2020-03-05Unspecified2020-03-20Wangping J, et al.
Basic reproduction number4.24Italy2.446.61Unspecified2020-03-15Unspecified2020-03-20Wangping J, et al.
Cumulative case count44993Italy1667696759Unspecified2020-03-15Unspecified2020-03-20Wangping J, et al.
Time from symptom onset to reporting7.3Italy120Unspecified2020-01-142020-03-082020-03-20Cereda D, et al.
Serial interval6.6Italy0.719Unspecified2020-01-142020-03-082020-03-20Cereda D, et al.
Doubling time2.6Italy2.23Unspecified2020-01-142020-03-082020-03-20Cereda D, et al.
Doubling time3.1Italy2.25.4Unspecified2020-01-142020-03-082020-03-20Cereda D, et al.
Doubling time3.5Italy2.74.8Unspecified2020-01-142020-03-082020-03-20Cereda D, et al.
Doubling time3.4Italy2.55Unspecified2020-01-142020-03-082020-03-20Cereda D, et al.
Basic reproduction number3.1Italy2.93.2Unspecified2020-01-142020-03-082020-03-20Cereda D, et al.
Basic reproduction number2.5Italy2.12.8Unspecified2020-01-142020-03-082020-03-20Cereda D, et al.
Basic reproduction number2.3Italy1.92.7Unspecified2020-01-142020-03-082020-03-20Cereda D, et al.
Basic reproduction number3.1Italy2.93.2Unspecified2020-01-142020-03-082020-03-20Cereda D, et al.
Basic reproduction number2.5Japan2.432.55Unspecified2020-01-142020-03-082020-03-16Sugishita Y, et al.
Effective reproduction number1.88Japan1.682.02Unspecified2020-01-142020-03-082020-03-16Sugishita Y, et al.
Cumulative case count1294Italy3903034UnspecifiedUnspecified2020-03-042020-03-13Jombart T, et al.
Cumulative case count202Spain95823UnspecifiedUnspecified2020-03-042020-03-13Jombart T, et al.
Cumulative case count592France1771705UnspecifiedUnspecified2020-03-042020-03-13Jombart T, et al.
Basic reproduction number3.8China3.54.2Unspecified2020-01-102020-01-232020-03-13Tang B, et al.
Basic reproduction number3China2.63.3Unspecified2020-01-192020-01-312020-03-13Tang B, et al.
Basic reproduction number2.6South Korea2.52.7Unspecified2020-01-232020-03-022020-03-13Tang B, et al.
Effective reproduction number0.9Singapore0.71Unspecified2020-01-212020-03-052020-03-12Amna Tari, et al.
Epidemic size294.4Singapore101.11239.7Unspecified2020-01-212020-03-052020-03-12Amna Tari, et al.
Growth rate1.1Singapore0.42Unspecified2020-01-212020-03-052020-03-12Amna Tari, et al.
Dispersion0.4Singapore0.1InfUnspecified2020-01-212020-03-052020-03-12Amna Tari, et al.
Basic reproduction number3.6Iran3.24.2Unspecified2020-02-192020-02-292020-03-10Muniz-Rodriguez K, et al.
Growth rate0.85Iran0.691Unspecified2020-02-192020-02-292020-03-10Muniz-Rodriguez K, et al.
Basic reproduction number3.58Iran1.298.46Unspecified2020-02-192020-02-292020-03-10Muniz-Rodriguez K, et al.
Doubling time1.2Iran1.051.44Unspecified2020-02-192020-02-292020-03-10Muniz-Rodriguez K, et al.
Ascertainment rate0.44Japan0.370.5UnspecifiedUnspecified2020-02-282020-03-10Omori R, et al.
Incubation period8.13China7.378.91Unspecified2020-01-122020-01-232020-03-10Qin J, et al.
Incubation period8.62China8.029.28Unspecified2020-01-122020-01-232020-03-10Qin J, et al.
Case fatality rate1.20%NA0.28%2.70%Unspecified2020-01-192020-02-202020-03-09Russell TW, et al.
Infection fatality ratio2.30%NA0.75%5.30%Unspecified2020-01-192020-02-202020-03-09Russell TW, et al.
Case fatality rate18%NA7.30%33%70-1302020-01-192020-02-202020-03-09Russell TW, et al.
Infection fatality ratio9%NA3.80%17%70-1302020-01-192020-02-202020-03-09Russell TW, et al.
Case fatality rate1.10%NA0.30%2.40%UnspecifiedUnspecified2020-03-032020-03-09Russell TW, et al.
Infection fatality ratio0.50%NA0.20%1.20%UnspecifiedUnspecified2020-03-032020-03-09Russell TW, et al.
Generation interval5.2Singapore3.786.78Unspecified2019-12-312020-02-262020-03-08Ganyani T, et al.
Serial interval5.21Singapore-3.3513.94Unspecified2019-12-312020-02-262020-03-08Ganyani T, et al.
Basic reproductive number1.27Singapore1.191.36Unspecified2019-12-312020-02-262020-03-08Ganyani T, et al.
Generation interval3.95China3.014.91Unspecified2019-12-312020-02-272020-03-08Ganyani T, et al.
Serial interval3.95China-4.4712.51Unspecified2019-12-312020-02-272020-03-08Ganyani T, et al.
Basic reproductive number1.59China1.421.78Unspecified2019-12-312020-02-272020-03-08Ganyani T, et al.
Incubation period6.6Singapore1.811.4Unspecified2020-01-192020-02-262020-03-06Tindale LC, et al.
Time from symptom onset to hospitalization5.9Singapore0.811Unspecified2020-01-192020-02-262020-03-06Tindale LC, et al.
Time from hospitalization to recovery13.3Singapore7.319.3Unspecified2020-01-192020-02-262020-03-06Tindale LC, et al.
Incubation period5.4China0.99.9Unspecified2020-01-212020-02-222020-03-06Tindale LC, et al.
Incubation period5.2China19.4Unspecified2020-01-212020-02-222020-03-06Tindale LC, et al.
Case fatality rate2.2ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-02-222020-03-06Tindale LC, et al.
Incubation period7.1Singapore6.18.3Unspecified2020-01-192020-02-262020-03-06Tindale LC, et al.
Incubation period5.46Singapore1.3411.1Unspecified2020-01-192020-01-312020-03-06Tindale LC, et al.
Incubation period7.27Singapore1.3117.3Unspecified2020-02-012020-02-262020-03-06Tindale LC, et al.
Incubation period9China7.9210.2Unspecified2020-01-212020-02-222020-03-06Tindale LC, et al.
Incubation period6.9China212.7Unspecified2020-01-212020-01-312020-03-06Tindale LC, et al.
Incubation period12.4China5.419Unspecified2020-02-012020-02-222020-03-06Tindale LC, et al.
Serial interval4.56Singapore2.696.42Unspecified2020-01-192020-02-262020-03-06Tindale LC, et al.
Serial interval4.22China3.435.01Unspecified2020-01-212020-02-222020-03-06Tindale LC, et al.
Incubation period4.8China4.25.4Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery20.3China19.421.3Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery21.2China20.222.30-92020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery17.5China15.32010-192020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery19.1China15.822.920-292020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery19.2China17.52130-392020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery19.2China1820.540-492020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery21.6China2023.450-592020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery22.4China20.824.160-692020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery22.9China21.224.770-1302020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery22.5China19.126.3Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery20.1China1921.3Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery20.3China19.521.1Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery28.3China25.331.6Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery19.3China17.920.9Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery21.2China20.422Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to recovery21.2China1824.9Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Secondary attack rate14.9China12.118.2Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Secondary attack rate9.6China7.911.8Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Serial interval6.3China5.27.6Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Effective reproduction number0.4China0.30.5Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to isolation2.7China2.13.3Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to isolation4.6China4.15Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to pcr confirmation3.18China2.653.76Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Time from symptom onset to pcr confirmation5.46China4.995.92Unspecified2020-01-142020-02-122020-03-04Qifang B, et al.
Basic reproduction number4.8China3.366.67Unspecified2020-01-112020-01-162020-03-03Anastassopoulou C, et al.
Basic reproduction number4.6China3.565.65Unspecified2020-01-112020-01-172020-03-03Anastassopoulou C, et al.
Basic reproduction number5.14China4.256.03Unspecified2020-01-112020-01-182020-03-03Anastassopoulou C, et al.
Basic reproduction number6.09China5.027.16Unspecified2020-01-112020-01-192020-03-03Anastassopoulou C, et al.
Basic reproduction number7.09China5.848.35Unspecified2020-01-112020-01-202020-03-03Anastassopoulou C, et al.
Symptomatic case fatality ratio2.94China2.93Unspecified2020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Basic reproduction number2.6ChinaUnspecifiedUnspecifiedUnspecified2020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Cumulative case count180000China45000760000Unspecified2020-01-112020-02-292020-03-03Anastassopoulou C, et al.
Basic reproduction number3.25China2.374.14Unspecified2020-01-112020-01-162020-03-03Anastassopoulou C, et al.
Basic reproduction number3.13China2.53.76Unspecified2020-01-112020-01-172020-03-03Anastassopoulou C, et al.
Basic reproduction number3.42China2.913.93Unspecified2020-01-112020-01-182020-03-03Anastassopoulou C, et al.
Basic reproduction number3.96China3.364.57Unspecified2020-01-112020-01-192020-03-03Anastassopoulou C, et al.
Basic reproduction number4.58China3.815.35Unspecified2020-01-112020-01-202020-03-03Anastassopoulou C, et al.
Basic reproduction number2ChinaUnspecifiedUnspecifiedUnspecified2020-01-112020-02-102020-03-03Anastassopoulou C, et al.
Cumulative case count8000000China72000037000000Unspecified2020-01-112020-02-292020-03-03Anastassopoulou C, et al.
Case fatality rate0.8-0.9ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-03-012020-03-03Rui Q, et al.
Case fatality rate5.4ChinaUnspecifiedUnspecifiedUnspecified2020-01-212020-03-012020-03-03Rui Q, et al.
Case fatality rate0.8-0.9ChinaNANAUnspecified2020-01-212020-03-012020-03-03Qi R, et al.
Case fatality rate5.4ChinaNANAUnspecified2020-01-212020-03-012020-03-03Qi R, et al.
Basic reproduction number2.2Cruise Ship2.12.4Unspecified2020-01-202020-02-202020-03-02Zhao S, et al.
Dispersion44Cruise Ship688Unspecified2020-01-202020-02-202020-03-02Zhao S, et al.
Cumulative case count3066Cruise Ship20463441Unspecified2020-01-202020-02-202020-03-02Zhao S, et al.
Doubling time4.6Cruise Ship39.3Unspecified2020-01-202020-02-202020-03-02Zhao S, et al.
Effective reproduction number1.5South Korea1.41.6Unspecified2020-01-202020-02-262020-03-02Shim E, et al.
Growth rate0.6South Korea0.50.7Unspecified2020-01-202020-02-262020-03-02Shim E, et al.
Cumulative case count79467China7157693855Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count64261China5822377895Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count46607China4081257678Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count13906China1274816092Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1410China13241550Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1265China12041364Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1369China12711559Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1136China10501279Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1100China10211273Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count1123China9481146Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count429China395486Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count356China334388Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count365China346393Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Cumulative case count430China407461Unspecified2020-01-212020-02-142020-02-20Fu X, et al.
Proportion of hospitalized cases admitted to icu0.05ChinaUnspecifiedUnspecifiedUnspecified2019-12-312020-02-182020-02-18Zhou G, et al.
Cumulative case count2868.7China1129.74607.7Unspecified2019-12-312020-01-232020-02-18Zhou G, et al.
Cumulative case count52185.4China2056483806.8Unspecified2020-01-232020-02-122020-02-18Zhou G, et al.
Cumulative case count45000ChinaUnspecifiedUnspecifiedUnspecified2019-12-312020-02-122020-02-18Wan K, et al.
Basic reproduction number1.44China1.41.47Unspecified2020-01-222020-02-122020-02-18Wan K, et al.
Cumulative case count453ChinaUnspecifiedUnspecifiedUnspecified2019-12-082020-01-222020-02-18Zhang B, et al.
Cumulative case count6333ChinaUnspecifiedUnspecifiedUnspecified2020-01-232020-02-132020-02-18Zhang B, et al.
Cumulative case count24333ChinaUnspecifiedUnspecifiedUnspecified2020-02-14Unspecified2020-02-18Zhang B, et al.
Effective reproduction number3.6ChinaUnspecifiedUnspecifiedUnspecified2019-12-082020-01-222020-02-18Zhang B, et al.
Effective reproduction number1.55ChinaUnspecifiedUnspecifiedUnspecified2020-01-232020-02-132020-02-18Zhang B, et al.
Effective reproduction number1.08ChinaUnspecifiedUnspecifiedUnspecified2020-02-14Unspecified2020-02-18Zhang B, et al.
Cumulative case count7710ChinaUnspecifiedUnspecifiedUnspecified2020-01-102020-01-222020-02-18Zhang B, et al.
Cumulative case count18832ChinaUnspecifiedUnspecifiedUnspecified2020-01-232020-02-132020-02-18Zhang B, et al.
Cumulative case count21342China2105721629Unspecified2020-02-14Unspecified2020-02-18Zhang B, et al.
Effective reproduction number3.4ChinaUnspecifiedUnspecifiedUnspecified2020-01-102020-01-222020-02-18Zhang B, et al.
Effective reproduction number0.83ChinaUnspecifiedUnspecifiedUnspecified2020-01-232020-02-132020-02-18Zhang B, et al.
Effective reproduction number0.59ChinaUnspecifiedUnspecifiedUnspecified2020-02-14Unspecified2020-02-18Zhang B, et al.
Cumulative case count7793ChinaUnspecifiedUnspecifiedUnspecified2020-01-232020-02-032020-02-18Zhang B, et al.
Cumulative case count13384ChinaUnspecifiedUnspecifiedUnspecified2020-02-04Unspecified2020-02-18Zhang B, et al.
Effective reproduction number3.3ChinaUnspecifiedUnspecifiedUnspecified2020-01-232020-02-032020-02-18Zhang B, et al.
Effective reproduction number0.63ChinaUnspecifiedUnspecifiedUnspecified2020-02-04Unspecified2020-02-18Zhang B, et al.
Time from symptom onset to reporting5.1China3.57.5Unspecified2019-12-312020-01-242020-02-17Jung S, et al.
Time from symptom onset to death15.2China13.117.7Unspecified2019-12-312020-01-242020-02-17Jung S, et al.
Cumulative case count6924China48859211Unspecified2019-12-082020-01-242020-02-17Jung S, et al.
Proportion of symptomatics that die5.30%China3.50%7.50%Unspecified2019-12-082020-01-242020-02-17Jung S, et al.
Basic reproduction number2.1China22.2Unspecified2019-12-082020-01-242020-02-17Jung S, et al.
Cumulative case count19289China1090130158Unspecified2019-12-082020-01-242020-02-17Jung S, et al.
Proportion of symptomatics that die8.40%China5.30%12.30%Unspecified2019-12-082020-01-242020-02-17Jung S, et al.
Basic reproduction number3.2China2.73.7Unspecified2019-12-082020-01-242020-02-17Jung S, et al.
Cumulative case count4090China39754206Unspecified2019-11-302020-01-112020-02-13Lin Q, et al.
Cumulative case count56833China5524258449Unspecified2019-11-302020-02-092020-02-13Lin Q, et al.
Cumulative case count110000China40000310000Unspecified2020-01-292020-02-022020-02-13Zhao H, et al.
Basic reproduction number7.05China6.118.18Unspecified2019-12-312020-01-232020-02-13Mizumoto K, et al.
Effective reproduction number3.24China3.163.32Unspecified2020-01-232020-02-132020-02-13Mizumoto K, et al.
Cumulative case count983006China7595751296258Unspecified2019-12-312020-02-132020-02-13Mizumoto K, et al.
Proportion of symptomatics that die0.0406ChinaUnspecifiedUnspecifiedUnspecified2019-12-312020-02-132020-02-13Mizumoto K, et al.
Cumulative case count3491China19247360Unspecified2019-12-012020-01-222020-02-11Chinazzi M, et al.
Cumulative case count58956China4076087471Unspecified2019-12-012020-01-222020-02-11Chinazzi M, et al.
Ascertainment rate0.1959China0.14360.3558Unspecified2019-12-012020-02-052020-02-11Chinazzi M, et al.
Incubation period4.2China3.55.1Unspecified2019-12-312020-02-102020-02-11Sanche S, et al.
Time from hospitalization to recovery11.5China817.3Unspecified2019-12-312020-02-102020-02-11Sanche S, et al.
Time from hospitalization to death11.2China8.714.9Unspecified2019-12-312020-02-102020-02-11Sanche S, et al.
Growth rate0.29China0.210.37Unspecified2019-12-312020-01-292020-02-11Sanche S, et al.
Cumulative case count4100China24236178Unspecified2019-12-312020-01-182020-02-11Sanche S, et al.
Cumulative case count18700China714138663Unspecified2020-01-192020-01-232020-02-11Sanche S, et al.
Growth rate0.14China0.120.15Unspecified2020-01-302020-02-102020-02-11Sanche S, et al.
Proportion of symptomatics that die0.18China0.110.81Unspecified2019-12-312020-02-052020-02-10Dorigatt I, et al.
Time from symptom onset to death22.3China1882Unspecified2019-12-312020-01-212020-02-10Dorigatt I, et al.
Cumulative case count24000China1300044000Unspecified2019-12-312020-01-312020-02-10Dorigatt I, et al.
Ascertainment rate0.0012China0.00090.0015Unspecified2020-01-012020-01-222020-02-09Cao Z, et al.
Cumulative case count35454ChinaUnspecifiedUnspecifiedUnspecifiedUnspecified2020-01-232020-02-09Cao Z, et al.
Basic reproduction number1.48ChinaUnspecifiedUnspecifiedUnspecified2019-12-172020-02-062020-02-08Hermanowic, et al.
Effective reproduction number1.06ChinaUnspecifiedUnspecifiedUnspecified2019-12-172020-02-082020-02-08Hermanowic, et al.
Basic reproduction number2.4 – 2.5ChinaUnspecifiedUnspecifiedUnspecified2019-12-172020-02-062020-02-08Hermanowic, et al.
Cumulative case count65000ChinaUnspecifiedUnspecifiedUnspecified2019-12-172020-02-062020-02-08Hermanowic, et al.
Doubling time2.4ChinaUnspecifiedUnspecifiedUnspecified2020-01-202020-02-022020-02-06Muniz-Rodriguez K, et al.
Proportion of hospitalized cases that die33China2937Unspecified2019-12-102020-01-272020-02-04Famular, et al.
Ascertainment rate1China0.62Unspecified2019-12-102020-01-272020-02-04Famular, et al.
Cumulative case count58000ChinaUnspecifiedUnspecifiedUnspecified2019-12-312020-01-312020-01-31Gardner L.
Cumulative case count95933ChinaUnspecifiedUnspecifiedUnspecified2019-12-312020-01-282020-01-30Ming W, et al.
Cumulative case count31200China2340040400Unspecified2019-12-312020-01-292020-01-29Vespignani A.
Incubation period4.6China3.35.7Unspecified2019-12-312020-01-252020-01-28Linton NM, et al.
Incubation period5China4.15.8Unspecified2019-12-312020-01-252020-01-28Linton NM, et al.
Time from symptom onset to hospitalization2.7China1.64.1Unspecified2019-12-312020-01-252020-01-28Linton NM, et al.
Time from symptom onset to death13.8China11.816Unspecified2019-12-312020-01-252020-01-28Linton NM, et al.
Time from hospitalization to death8.3China6.410.5Unspecified2019-12-312020-01-252020-01-28Linton NM, et al.
Time from symptom onset to isolation2.9ChinaUnspecifiedUnspecifiedUnspecified2019-12-292020-01-232020-01-26Liu T, et al.
Proportion of symptomatics that die0.03ChinaUnspecifiedUnspecifiedUnspecified2019-12-292020-01-232020-01-26Liu T, et al.
Incubation period5.4China4.26.7Unspecified2019-12-102020-01-252020-01-26Famular, et al.
Basic reproduction number2.6China1.53.5UnspecifiedUnspecified2020-01-182020-01-24Imai N, et al.
Date of emergenceUnspecifiedChina2020-11-192020-12-19UnspecifiedUnspecifiedUnspecified2020-01-23Neher R, et al.
Basic reproduction number2.2China1.43.8Unspecified2019-11-272020-01-182020-01-23Riou J, et al.
Basic reproduction numberUnspecifiedChina1.53.5Unspecified2019-11-012020-01-012020-01-23Neher R, et al.
Dispersion0.54China0.0146.95Unspecified2019-11-272020-01-182020-01-23Riou J, et al.
Cumulative case count4000China10009700Unspecified2020-01-182020-01-182020-01-22Imai N, et al.

Software Catalog

Listing of software created by community members, with documented metadata. (Click on a software name to open the software webpage.)
software typesoftware nameCreator(s)
DashboardDistribution of new coronavirus pneumoniaChina Centers for Disease Control
DashboardCoronavirus COVID-19 Global Cases by Johns Hopkins CSSEGardner L, et al.
DashboardCOVID-19 Surveillance DashboardUniversity of Virginia
DashboardCOVID-19 Cases and Clusters Outside of ChinaUniversity of Virginia
DashboardCOVID-19European Centre for Disease Prevention and Control
DashboardNovel Coronavirus (COVID-19) Infection MapZhao B, et al.
Dashboard2019nCoV-DashboardThe Center for the Ecology of Infectious Diseases (CEID) at the University of Georgia
DashboardCOVID-19 Italy – Situation monitoringItalian Department of Civil Protection
Data processingStats of the ‘2019-nCov’ CasesYu G, et al.
Data processingscrapRKucharski A
ModelingNobBS: Nowcasting by Bayesian SmoothingMcGough S, et al.
ModelingA stochastic model for the transmission of 2019-nCov in WuhanThe Center for the Ecology of Infectious Diseases (CEID) at the University of Georgia
ModelingEstimation of the effective reproduction number of COVID-19 outside ChinaThe Center for the Ecology of Infectious Diseases (CEID) at the University of Georgia
ModelingExtended state-space SIR epidemiological modelsSong Lab, et al.
ModelingPandemic EstimatorAkuukis
ModelingEpiNow: Estimate Realtime Case Counts and Time-varying Epidemiological ParametersAbbott S, et al.
VisualizationAlerts for Novel Coronavirus (2019-nCoV)HealthMap
VisualizationNovel Coronavirus (2019-nCoV)Brownstein J, et al.
VisualizationCoronavirus Map: Tracking the Spread of the OutbreakLai R KK, et al.
VisualizationRealtime interactive map of coronavirus 2019-nCov global distributionMalishev M
VisualizationCOVID-19 Confirmed and Forecasted Case DataOstus D, et al.
VisualizationTemporal variation in transmission during the COVID-19 outbreakAbbott S, et al.
VisualizationInteractive Visualization for the Analysis of Bed Capacities for Covid-19 PatientsData Analysis and Visualization Group at the University of Konstanz

COVID-19 GitHub Repository

The MIDAS Network has created a GitHub Repository for COVID-19 modeling research. The repository includes data and information, listed on this website, in computational form, mostly structured CSV files and rich metadata.

Directly access content on the COVID-19 GitHub repository:

Parameter Estimates

Published estimates of epidemiological characteristics, encoded by community members and approved by authors.

Software Catalog

Listing of software created by community members, with documented metadata.

Documents

Reports, pre-prints, and peer-reviewed papers relevant to COVID-19 modeling, organized by country or by topic. All documents are also listed in a downloadable format.

How to Participate

Mailing List:

Any infectious disease scientist, practitioner, or student interested in COVID-19 modeling research can join this mailing list. Subscription requests will be reviewed and approved by a moderator.

Contribute to the MIDAS COVID-19 Repository:

We encourage community members to contribute resources to the repository and thus support the overall COVID-19 research effort. See the information for contributors section on the GitHub repository for guidance on how to contribute material to the repository. Contributions can be made via pull request or by submitting an issue. Contact questions@midasnetwork.us for any questions or ideas for improvements, or to send/request any material to be included.

Join the Slack COVID-19 Workspace:

A Slack workspace is being maintained by Caitlin Rivers (caitlin.rivers@gmail.com). The workspace includes various channels: general, importation, news, random, publications, forecasting, data, and announcements.

Review COVID-19 Preprints on Outbreak Science Rapid PREreview Platform:

This rapid pre-review platform enables the community to give feedback on pre-prints coming out with modeling and other analyses of the COVID-19 and other outbreaks. Visit the platform here.

For questions or concerns, contact the MIDAS Coordination Center via questions@midasnetwork.us.

MIDAS Members Working on COVID-19
Darcy Rao

Acting Assistant Professor
University of Washington
Donald Burke

Distinguished University Professor of Health Science and Policy
University of Pittsburgh
Gloria Kang

Postdoctoral Fellow
Centers for Disease Control and Prevention
Jin Wang

Professor and UNUM Chair of Excellence
University of Tennessee Chattanooga
Kim Wong

Research Assistant Professor
University of Pittsburgh
M Halloran

Faculty Member
Fred Hutchinson Cancer Research Center
Marc Choisy

Senior Research Scientist
French National Institute for Sustainable Development
Mark Jit

Professor of Vaccine Epidemiology
London School of Hygiene & Tropical Medicine
Steven Riley

Professor of Infectious Disease Dynamics
Imperial College London
W Edmunds

Professor of Infectious Disease Modelling
London School of Hygiene & Tropical Medicine
Wei Luo

Research Associate
Boston Children’s Hospital
Yao Li

Doctoral Candidate
University of Maryland

MIDAS-2


MIDAS Coordination Center
University of Pittsburgh

A737 Public Health
130 DeSoto Street
Pittsburgh PA 15261

MIDAS Newsletter Signup

MIDAS Membership Request Form

MIDAS 2019 Coronavirus Mailing List Signup

questions@midasnetwork.us